Inventiva (NASDAQ:IVA) Sees Strong Trading Volume – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw an uptick in trading volume on Monday. Approximately 2,856,577 shares traded hands during mid-day trading, an increase of 196% from the previous session’s volume of 966,662 shares. The stock last traded at $2.9650 and had previously closed at $2.94.

Analyst Upgrades and Downgrades

Several brokerages have commented on IVA. Guggenheim increased their target price on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Weiss Ratings lowered Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. Truist Financial boosted their price target on Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Finally, Cantor Fitzgerald started coverage on Inventiva in a report on Friday, July 17th. They set an “overweight” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $15.86.

Inventiva Stock Performance

The business’s fifty day moving average price is $3.98 and its 200-day moving average price is $4.43.

Inventiva (NASDAQ:IVA) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The firm had revenue of $0.75 million for the quarter. As a group, sell-side analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Inventiva

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP bought a new stake in Inventiva in the 1st quarter worth approximately $1,111,000. Engineers Gate Manager LP raised its stake in Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after buying an additional 43,280 shares during the last quarter. Finally, Platt Investment Counsel LLC bought a new position in shares of Inventiva during the 3rd quarter valued at $45,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.